Burden of diabetic macular oedema in patients receiving antivascular endothelial growth factor therapy in South Korea: a healthcare resource use and cost analysis.

ABSTRACT:

Objective

To examine healthcare resource utilisation (HRU) and direct medical costs for patients with diabetic macular oedema (DME) treated with antivascular endothelial growth factor (anti-VEGF) in Korea by comparing with those for (1) patients with diabetes mellitus (DM) without retinopathy and (2) patients with neovascular age-related macular degeneration (nAMD) treated with anti-VEGF.

Design

Retrospective cohort study.

Setting

The Korean National Health Insurance (NHI) database from 1 January 2014 to 31 December 2016.

Participants

We identified 1398 patients older than 30 years of age who received anti-VEGF treatment for DME in 2015 after excluding patients who had a diagnosis of nAMD in 2015 and any cancer in the preceding year.

Main outcome measures

SUBMITTER: Jeon HL 

PROVIDER: S-EPMC7778761 | biostudies-literature | 2020 Dec

REPOSITORIES: biostudies-literature